Look after the COVID‐19 pandemic: Mortality rates among patients with rheumatic diseases

Look after the COVID‐19 pandemic: Mortality rates among patients with rheumatic diseases

Aim Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) infection may have a more severe course in patients with underlying disease or who have had immunosuppression. In this study, it was aimed to determine the frequency of coronavirus disease 2019 (COVID‐19) and the mortality rates relate...

Full description

Saved in:
Bibliographic Details
Published in:International journal of rheumatic diseases Vol. 27; no. 3; pp. e15129 - n/a
Main Authors: Çimen Güneş, Ezgi, Çolak, Seda, Şenlik, Zeynep B., Tekgöz, Emre, Altunay, Kerime, Özdemirkan, Tuğba, Aytaç, Baran C., Şimşek, Asiye Ç., Çınar, Muhammet, Yılmaz, Sedat
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01-03-2024
Subjects:
Adrenal Cortex Hormones
Adult
Coronaviruses
Corticosteroids
COVID-19
Cyclophosphamide
Female
Humans
Hydroxychloroquine
Immunosuppression
Immunosuppressive agents
Immunosuppressive Agents - therapeutic use
Infections
Inflammatory diseases
Male
Middle Aged
Mortality
Mycophenolate mofetil
Mycophenolic acid
Pandemics
Patients
Retrospective Studies
Rheumatic diseases
Rheumatic Diseases - diagnosis
Rheumatic Diseases - drug therapy
Rheumatic Diseases - epidemiology
Rheumatology
Rituximab
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Steroids
COVID‐19
mortality
rheumatic diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) infection may have a more severe course in patients with underlying disease or who have had immunosuppression. In this study, it was aimed to determine the frequency of coronavirus disease 2019 (COVID‐19) and the mortality rates related to COVID‐19 among patients with rheumatic disease. Methods The patients who were followed up with rheumatic disease in the rheumatology outpatient clinic in a tertiary hospital were retrospectively assessed if they had COVID‐19 infection or not between March 2020 and January 2022. Results A total of 10 682 patients were evaluated. There were 2928 (27.4%) COVID‐19‐positive and 7754 (72.6%) COVID‐19‐negative patients. The mean age of COVID‐19‐positive patients was 46.2 ± 14.6 years, and 65.8% were female. Forty‐two (1.4%) patients died due to COVID‐19. Among COVID‐19‐negative patients, 192 patients died. The most common rheumatic disease among patients with COVID‐19 was spondyloarthritis (SpA) (30.4%). Corticosteroids were the most common treatment agent in COVID‐19‐positive patients regardless of mortality. Thirty‐one (73.8%) patients were receiving corticosteroids, and 35 (83.3%) patients were receiving immunosuppressive agents among patients with mortality. According to the logistic regression analysis, older age, male gender, and receiving corticosteroid, hydroxychloroquine, mycophenolate mofetil, tofacitinib, rituximab, and cyclophosphamide were found to be related to increased mortality. Conclusion COVID‐19 is a serious infection and the current study emphasized that patients with rheumatic diseases had increased mortality rates, particularly in patients who were old, male, and on immunosuppressive treatments.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1756-1841
1756-185X
DOI:10.1111/1756-185X.15129